8月11日 - ** 生物技术公司 FibroBiologics（FBLG.O）的股价在盘前交易中上涨 2%，至 1.00 美元
** 该公司表示，美国专利局已授予一项专利，该专利涉及利用成纤维细胞改善1型糖尿病胰岛细胞移植的技术。1型糖尿病是一种自身免疫性疾病，患者体内会破坏产生胰岛素的细胞
** 该专利旨在提高移植胰岛的存活率和长期功能，从而解决胰岛移植中的关键难题
** 公司表示，该技术通过减少移植胰岛的损失，可帮助更多患者从每例捐赠胰腺中获益
** 称成纤维细胞可能促进血管形成、减轻细胞应激并支持移植组织的存活
** 补充说明，该专利在糖尿病领域之外，还可能应用于其他细胞和组织移植手术
** 截至上一交易日收盘，该股年内累计跌幅约为78%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.